drugset / Trial / NCT03015961

Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery

NCT03015961 ↗

Phase 4 Terminated 38 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary Objective: The primary objective of this study is to compare postsurgical pain control following local infiltration analgesia (LIA) with EXPAREL admixed with bupivacaine HCl versus LIA with bupivacaine HCl in adult subjects undergoing open lumbar posterior spinal fusion surgery. Secondary Objectives: The secondary objectives of this study are to compare additional efficacy, safety, and health economic outcomes following LIA with EXPAREL admixed with bupivacaine HCl versus LIA with bupivacaine HCl in adult subjects undergoing open lumbar posterior spinal fusion surgery.

Timeline

Start
2017-02-21
Primary completion
2017-10-30
Completion
2017-10-30

Outcome

Outcome not reported

Stopped (Enrollment): “Slow enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 0.5 % Other
Comparator Bupivacaine Other / unclassified 266 mg Other

Indications

No indication recorded.